Gamida Cell Ltd. (NASDAQ:GMDA) Q3 2023 Earnings Conference Call November 14, 2023 8:30 AM ET

Company Participants

Mike Kuczkowski - Corporate Communications

Abbey Jenkins - President & Chief Executive Officer

Michele Korfin - Chief Operating Officer & Chief Commercial Officer

Ronit Simantov - Chief Medical Officer & Chief Scientific Officer

Terry Coelho - Chief Financial Officer

Conference Call Participants

Gil Blum - Needham & Co.

Operator

Ladies and gentlemen, thank you for standing by. Welcome to Gamida Cell's Conference Call for Third Quarter 2023 Financial Results. My name is Chris, and I'll be your operator for today's call. Please be advised that this call is being recorded at Gamida Cell's request.

I would now like to introduce your host for today's conference, Mike Kuczkowski of Gamida Cell Corporate Communications. Mike, please go ahead.

Mike Kuczkowski

Thank you, and good morning, everyone. Welcome to today's call, during which we will provide an update on the company and review our financial results for the third quarter of 2023. Earlier this morning, we issued a press release summarizing our financial results and providing a business update, which is available on our website at www.gamida-cell.com.

Here with me on our call today are Abbey Jenkins, President and Chief Executive Officer; Michele Korfin, Chief Operating Officer and Chief Commercial Officer; Ronit Simantov, Chief Medical Officer and Chief Scientific Officer; and Terry Coelho, our Chief Financial Officer.

Before we begin, I want to remind everyone that during this call, we may make forward-looking statements about our future expectations and plans, including with respect to the potentially life-saving or curative therapeutic potential of Omisirge Omidubicel-onlv; the company cell therapy candidate GDA-201, expectations regarding the commercial launch of Omisirge and its potential to capture market share and generate revenue. Gamida Cell's plans for commercial or strategic partnerships to support the launch of Omisirge, Gamida Cell's financial runway, Gamida Cell's ability to keep its Israel facilities open, the state of its workforce and future developments that may adversely impact Gamida Cell's Israel operations.

Our actual results may differ materially from what we project today due to a number of important factors, including those related to clinical, scientific, regulatory and technical developments and those inherent in the process of developing and commercializing products candidates that are safe and effective for use as human therapeutics and in the endeavor of building a business around our product and product candidate, as well as those considerations described in the Risk Factors section of our most recent quarterly report on Form 10-Q and other filings that we may make with the SEC from time to time.